Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPER
NCT06222268Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol, dronabinol in post-traumatic stress disorder (PTSD). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06222268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222268.